Drug
CC-223 clinical trials
Also written CC-223 and ATG-008.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
10 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 2
Celgene (5) · Antengene Therapeutics Limited (1) · Antengene Corporation (1) · Shanghai Antengene Corporation Limited (1) · Qi Zhou (1) · Sichuan University (1)
Often tested with
Tested in the same studies.
Selinexor (2) · Erlotinib (1) · Cc-486 (1) · Avadomide (1) · Spebrutinib (1) · Toripalimab (1)
Studies
Open first, then newest update. How each study uses CC-223 is read from its arms, and is right about nine times in ten.
Testing it · 10
- Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular LymphomaTerminatedPhase 1CelgeneNCT02031419Written as CC-223
- Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) SubjectsTerminatedPhase 2Antengene Therapeutics LimitedNCT03591965Written as ATG-008
- A Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaTerminatedPhase 1Antengene CorporationNCT05354362Written as ATG-010 and ATG-008
- A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)TerminatedPhase 2Shanghai Antengene Corporation LimitedNCT04518137Written as ATG-008 30 mg, orally, QD, each 4 week (28-day) a cycle
- Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple MyelomaCompletedPhase 1/2CelgeneNCT01177397Written as CC-223
- A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH )Status unknownPhase 2Qi ZhouNCT04998760Written as ATG-008
- ATG-008 Combined With Toripalimab in Advanced Solid TumorsStatus unknownPhase 1/2Sichuan UniversityNCT04337463Written as ATG-008
- A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult SubjectsCompletedPhase 1CelgeneNCT01611467Written as CC-223
- CC-223 and Ketoconazole Drug-Drug Interaction StudyCompletedPhase 1CelgeneNCT01896323Written as CC-223
- Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung CancerCompletedPhase 1CelgeneNCT01545947Written as CC-223, erlotinib